AstraZeneca announced an agreement to acquire EsoBiotec
AstraZeneca shared a post on LinkedIn:
“For Investors and Media.
Today we announced an agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies.
We believe EsoBiotec’s world-leading in vivo cell therapy platform has the potential to transform cell therapy, increasing the number of patients that may be able to access and benefit from these innovative treatments.
Traditional cell therapies require cells be removed from a patient, genetically modified outside of the body, and then readministered to the patient as a medicine after immune cell depletion, a process that typically takes weeks. In vivo cell therapy enables administration of cell therapies in minutes, through a simple IV injection and without the need for immune cell depletion.
By engineering immune cells directly within the patient’s body, the platform offers a promising approach to streamline processes, reducing complexities and manufacturing timelines, while increasing patient access.”
More posts featuring AstraZeneca.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023